Literature DB >> 26367100

New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.

F David Carmona1, Javier Martín1, Miguel A González-Gay2.   

Abstract

Giant cell arteritis is a complex immune-mediated disease that involves large blood vessels in individuals older than 50 years. Recent studies have confirmed a strong association of this form of vasculitis with the HLA region, particularly with HLA class II genes. However, other non-HLA loci, such as protein tyrosine phosphatase non-receptor type 22, may also account for the susceptibility to giant cell arteritis. In addition, genetic variants located in genes encoding proinflammatory cytokines seem to influence the phenotypic expression of the disease, including the risk of severe ischemic complications, the presence of polymyalgia rheumatica and the higher incidence of relapses observed in some patients. The identification of putative genetic markers of disease severity could have clear therapeutic implications, as it may allow us to identify patients who are potentially responders to specific treatments.

Entities:  

Keywords:  IFN-γ; IL-6; giant cell arteritis; human leukocyte antigen; polymyalgia rheumatica; protein tyrosine phosphatase non-receptor type 22; relapses; temporal artery biopsy; vascular endothelial growth factor; visual ischemic complications

Mesh:

Substances:

Year:  2015        PMID: 26367100     DOI: 10.1586/1744666X.2016.1089173

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  9 in total

1.  [Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)].

Authors:  J C Henes; H Schulze-Koops; M Witt; H P Tony; F Mueller; M Grunke; M Czihal; T Dörner; F Proft
Journal:  Z Rheumatol       Date:  2018-02       Impact factor: 1.372

Review 2.  A new era for giant cell arteritis.

Authors:  H S Lyons; V Quick; A J Sinclair; S Nagaraju; S P Mollan
Journal:  Eye (Lond)       Date:  2019-10-03       Impact factor: 3.775

Review 3.  Giant Cell Arteritis: 2018 Review.

Authors:  Anne Winkler; David True
Journal:  Mo Med       Date:  2018 Sep-Oct

4.  A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.

Authors:  F David Carmona; Augusto Vaglio; Sarah L Mackie; José Hernández-Rodríguez; Paul A Monach; Santos Castañeda; Roser Solans; Inmaculada C Morado; Javier Narváez; Marc Ramentol-Sintas; Colin T Pease; Bhaskar Dasgupta; Richard Watts; Nader Khalidi; Carol A Langford; Steven Ytterberg; Luigi Boiardi; Lorenzo Beretta; Marcello Govoni; Giacomo Emmi; Francesco Bonatti; Marco A Cimmino; Torsten Witte; Thomas Neumann; Julia Holle; Verena Schönau; Laurent Sailler; Thomas Papo; Julien Haroche; Alfred Mahr; Luc Mouthon; Øyvind Molberg; Andreas P Diamantopoulos; Alexandre Voskuyl; Elisabeth Brouwer; Thomas Daikeler; Christoph T Berger; Eamonn S Molloy; Lorraine O'Neill; Daniel Blockmans; Benedicte A Lie; Paul Mclaren; Timothy J Vyse; Cisca Wijmenga; Yannick Allanore; Bobby P C Koeleman; Jennifer H Barrett; María C Cid; Carlo Salvarani; Peter A Merkel; Ann W Morgan; Miguel A González-Gay; Javier Martín
Journal:  Am J Hum Genet       Date:  2016-12-29       Impact factor: 11.025

5.  Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy.

Authors:  F David Carmona; Patrick Coit; Güher Saruhan-Direskeneli; José Hernández-Rodríguez; María C Cid; Roser Solans; Santos Castañeda; Augusto Vaglio; Haner Direskeneli; Peter A Merkel; Luigi Boiardi; Carlo Salvarani; Miguel A González-Gay; Javier Martín; Amr H Sawalha
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

6.  Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Authors:  Clément Brault; Anders H Riis; Anil Mor; Pierre Duhaut; Reimar W Thomsen
Journal:  Clin Epidemiol       Date:  2018-10-16       Impact factor: 4.790

7.  A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility.

Authors:  David González-Serna; Elio G Carmona; Norberto Ortego-Centeno; Carmen P Simeón; Roser Solans; José Hernández-Rodríguez; Carlos Tolosa; Santos Castañeda; Javier Narváez; Ferran Martinez-Valle; Torsten Witte; Thomas Neumann; Julia Holle; Lorenzo Beretta; Luigi Boiardi; Giacomo Emmi; Marco A Cimmino; Augusto Vaglio; Ariane L Herrick; Christopher P Denton; Carlo Salvarani; María C Cid; Ann W Morgan; Carmen Fonseca; Miguel A González-Gay; Javier Martín; Ana Márquez
Journal:  PLoS One       Date:  2018-12-26       Impact factor: 3.240

8.  PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases.

Authors:  Giuseppe A Ramirez; Patrizia Rovere-Querini; Miriam Blasi; Silvia Sartorelli; Maria Chiara Di Chio; Mattia Baldini; Rebecca De Lorenzo; Enrica P Bozzolo; Roberto Leone; Alberto Mantovani; Angelo A Manfredi; Enrico Tombetti
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

9.  New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword?

Authors:  Ana M Anzola; Laura Trives; Julia Martínez-Barrio; Blanca Pinilla; José María Álvaro-Gracia; Juan Molina-Collada
Journal:  Clin Rheumatol       Date:  2022-02-03       Impact factor: 3.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.